dostarlimab
gsk
['rectal']
 breaking #asco22 news: breakthrough findings published in by msk experts &amp; luis diaz show 100% complete response rate in all patients who received #immunotherapy treatment for mismatch repair deficient locally advanced #rectalcancer. 
The official account of Memorial Sloan Kettering Cancer Center, the Sloan Kettering Institute, and Louis V. Gerstner, Jr. Graduate School of Biomedical Sciences